Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PADRE-CMV fusion peptide vaccine
- Development stage
- Phase 1
- Lead developer
- City of Hope National Medical Center
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
The PADRE-CMV fusion peptide vaccine is a synthetic peptide-based investigational immunotherapy designed to elicit cytomegalovirus (CMV)-specific T cell responses. It consists of the HLA A*0201-restricted CMV pp65(495-503) cytotoxic CD8+ T-cell epitope fused to the synthetic Pan DR epitope (PADRE), which serves as a universal helper T cell epitope. The goal is to stimulate both CD4+ and CD8+ T cell immunity against CMV, particularly in settings such as hematopoietic cell transplantation where reactivation or primary infection with CMV can cause significant morbidity. Clinical studies have shown that the vaccine has an acceptable safety profile and can expand pp65-specific T cells in healthy adults, especially when administered with the adjuvant PF03512676[1][2][4]. The product has been evaluated in phase 1 clinical trials for its safety and immunogenicity.
- Other names
- PADRE-CMV peptide vaccinePADRE-cytomegalovirus fusion peptide vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on PADRE-CMV fusion peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PADRE-CMV fusion peptide vaccine.